Table 1. Molecularly Targeted Agents for Tumors of the Central Nervous System.
| COMPOUND | MOLECULAR TARGET | RESULTS FROM CLINICAL TRIALS FOR GBM | NUMBER OF CLINCAL TRIALS |
|---|---|---|---|
| Cediranib | VEGFR 1,2,3 | Median OS in 16 patients of 211 days (Ref. 48) 6-month PFS 25.8 %, PR in 56.7 % (Ref. 49) |
6 |
| Dasatinib | Bcr-Abl, C-kit, PDGFR, Src | No Published Results | 4 |
| Erlotinib | EGFR | 6-month PFS 3.1% (Ref. 35) Median survival 19.3 months (Ref. 36) 6-month PFS of 3 %, 12-month survival of 57 % (Ref. 37) Median PFS 2.8 months, median OS 8.6 months (Ref. 38) |
20 |
| Everolimus | mTOR | stable disease in 36%, PR in 14 % of patients (Ref. 57) | 11 |
| Gefitinib | EGFR | Median EFS 8.1 weeks, median OS 39.4 weeks (Ref. 34) Median time to progression 8.4 weeks, 6-month PFS 14.3%, median OS 24.6 weeks (Ref. 33) |
4 |
| Imatinib | Bcr-Abl, C-kit, PDGFR | 6-month PFS 3% (Ref. 44) 6-month PFS 16% (Ref. 45) 6-month PFS 27%, median PFS 14.4 week (Ref. 185) 24% progression-free at 6 months (Ref. 186) |
7 |
| Lapatanib | EGFR2 | No Published Results | 3 |
| Pazopanib | C-kit, PDGFR, VEGFR 1,2,3 | No Published Results | 1 |
| Sirolimus | mTOR | 6-month PFS of 3.1% (Ref. 35) | 4 |
| Sorafenib | C-kit, PDGFR, Raf | Median PFS 6 months, median OS 16 months (Ref. 187) | 7 |
| Sunitinib | VEGFR 2,3, C-kit, FLT3, PDGFR | Median TTP 1.5 months and OS 3 months (Ref. 188) | 8 |
| Temsirolimus | mTOR | 6-month PFS 7.8 %, median OS 4.4 months (Ref. 58) | 9 |
| Vandetanib | EGFR, VEGFR | No Published Results | 10 |
| Vatalanib | C-kit, PDGFR, VEGFR1,2,3 | Partial Response in 29 % patients (Ref. 189) | 2 |
OS, overall survival; PFS, progression-free survival; PR, partial response; EFS, event-free survival; TTP, time to progression.
Number of clinical trials are determined from the clinical trials that have either been completed or are ongoing for therapy in glioma, searched on www.clinicaltrial.gov on 1st Dec 2010.